Biospecimen Collection (NCT06672146)

Name: Biospecimen Collection trial for Acute Myeloid Leukemia (NCT06672146)
Uploaded: 2026-10-31T05:34:43.112Z
Duration: 1 min 14 s
Description: Biospecimen Collection trial for Acute Myeloid Leukemia (NCT06672146). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06672146.

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial): a one-minute explainerNCT066721461 min

Biospecimen Collection trial for Acute Myeloid Leukemia (NCT06672146). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for newly diagnosed, untreated IDH2-mutated acute myeloid leukemia, assigned through myeloMATCH. Patients must be 60 or older, or adults unsuitable for cytarabine-based induction.

The idea: compare oral decitabine/cedazuridine and venetoclax with or without enasidenib after a safety lead-in. Enasidenib blocks mutant IDH2, aiming to restore cell maturation. Venetoclax blocks a survival protein; cedazuridine slows decitabine breakdown. Researchers compare remission without detectable residual disease after two cycles.

This phase 2 study plans 93 patients. Eric Huselton leads through SWOG; 125 US locations list recruitment.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.